Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 82 (10), 1682-8

Quantitation of Fas and Fas Ligand Gene Expression in Human Ovarian, Cervical and Endometrial Carcinomas Using Real-Time Quantitative RT-PCR

Affiliations

Quantitation of Fas and Fas Ligand Gene Expression in Human Ovarian, Cervical and Endometrial Carcinomas Using Real-Time Quantitative RT-PCR

H Das et al. Br J Cancer.

Abstract

Alterations in the expression of Fas (CD95/APO-1) and its ligand (FasL) have been demonstrated in various types of cancers as a mechanism for tumour cell to escape from the immune system. In the present study, we evaluated the expression of the Fas and FasL genes in a wide range of primary gynaecological carcinomas. These included 31 ovarian, 29 cervical and 25 endometrial carcinoma tissues as well as four ovarian and three cervical carcinoma cell lines. Our real-time quantitative reverse transcription polymerase chain reaction analysis revealed that down-regulation of Fas expression is more prominent than the up-regulation of FasL expression in all types of gynaecological cancer studied. This down-regulation of Fas expression was also true for the seven carcinoma cell lines. Only one cervical carcinoma cell line, DoT, exhibited a high level of FasL expression. These results indicated that down-regulation of Fas expression is a common abnormality in many types of cancers including gynaecological cancers, whereas an increase in FasL expression is not a common phenomenon in these cancers.

Similar articles

See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles

References

    1. Cancer Res. 1998 Aug 1;58(15):3391-400 - PubMed
    1. Leukemia. 1995 May;9(5):815-20 - PubMed
    1. Oncogene. 1995 Jun 15;10(12):2397-401 - PubMed
    1. Nature. 1995 Oct 19;377(6550):630-2 - PubMed
    1. Science. 1995 Nov 17;270(5239):1189-92 - PubMed

Publication types

MeSH terms

Feedback